| The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity. | |
| | |
MedLine Citation:
|
PMID: 20189243 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To enable selective cell-kill, we designed functionalized lipid vesicles with pH-triggered heterogeneous membranes and encapsulated doxorubicin that exhibit tunable surface topography. These vesicles "hide" (mask) the targeting ligands from their surface during circulation in the blood, and only progressively "expose" these ligands as they gradually penetrate deeper into the tumor interstitium, where after endocytosis they burst release their contents. The stimulus to activate the binding reactivity is the pH gradient between the blood stream (pH 7.4-7.0) and the increasingly acidic pH inside the tumor interstitium (pH 6.7-6.5). Doxorubicin release is activated at the endosomal pH 5.5-5.0. We show that tunable functionalized vesicles exhibit environmentally-dependent (pH-dependent) association with cancer cells resulting in high cell-kill selectivity. When lowering the extracellular pH from 7.4 to 6.5, tunable functionalized vesicles deliver doxorubicin to cancer cells that increases from 41% to 93% of maximum resulting in cancer cell killing that increases from 23 to 71% of maximum, respectively. This proof-of-concept shows the potential of tunable targeted liposomal chemotherapy to selectively kill cancer cells in an environmentally-dependent way. |
| | |
Authors:
|
Shrirang Karve; Amey Bandekar; Md R Ali; Stavroula Sofou |
Related Documents
:
|
17040223 - Optimum melanin production using recombinant escherichia coli. 12846683 - Positioning of the ph-probe by manometry or radiography for monitoring of the esophagus... 20057573 - A heated absorption cell for studying infrared absorption bands. |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-02-26 |
Journal Detail:
|
Title: Biomaterials Volume: 31 ISSN: 1878-5905 ISO Abbreviation: Biomaterials Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-03-22 Completed Date: 2010-06-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8100316 Medline TA: Biomaterials Country: England |
Other Details:
|
Languages: eng Pagination: 4409-16 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Chemical and Biological Engineering, Polytechnic Institute of NYU, 6 MetroTech Center, Brooklyn, NY 11201, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibiotics, Antineoplastic*
/
administration & dosage,
chemistry,
pharmacology Calorimetry, Differential Scanning Cell Line, Tumor / drug effects* Doxorubicin* / administration & dosage, chemistry, pharmacology Drug Delivery Systems / methods* Drug Screening Assays, Antitumor Humans Hydrogen-Ion Concentration Lipids / chemistry* Materials Testing Models, Molecular |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Lipids; 23214-92-8/Doxorubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nan...
Next Document: In vitro and in vivo performance of a dual drug-eluting stent (DDES).